A phase 2 trial of the GSK‐3 inhibitor tideglusib in progressive supranuclear palsy

Tolosa, Eduardo, Litvan, Irene, Höglinger, Günter U., Burn, David, Lees, Andrew, Andrés, María V., Gómez‐Carrillo, Belén, León, Teresa +2 more·2014·Movement Disorders
DOI 10.1002/mds.25824

Cited by (326)

Items 301–326 of 326

  1. Cross-sectional and longitudinal validation of short and long versions of the progressive supranuclear palsy quality of life scale
    Qi Shen, Yi-Xin Zhao, Gan Tang, Qin Zhang, KunWang Chan, Lu Feng, Xiaoniu Liang, Jian-Jun Wu, Jian Wang, Xinyi Li et al. · 2025 · Journal of Neural Transmission
  2. Progressive Supranuclear Palsy
    Marcello Cherchi · 2025 · Springer eBooks
  3. Treatment of Frontotemporal Dementias
    Doris Chen, Lawren A. VandeVrede, Adam L. Boxer · 2025 · Cambridge University Press eBooks
  4. Additional file 1 of Application of Bayesian methods to accelerate rare disease drug development: scopes and hurdles
    KM Kidwell, Satrajit Roychoudhury, Wendelberger, Barbara, John Scott, Tara Moroz, Shaoming Yin, Madhurima Majumder, John Zhong, Raymond A. Huml, Miller, Veronica · 2022 · Figshare
  5. Targeting Soluble VCAM1 and GSK3β Improves Cerebrovascular Function and Reduces Stroke Pathology in Diabetic Mice
    Masuma Akter Brishti, Mousumi Mandal, Udai Pratap Singh, Tauheed Ishrat, Marie Dennis Leo · 2026 · Cells
  6. Biological Insights into Neurodegenerative Disorders and the Use of Drug Repurposing for Their Treatment
    Pratik Talukder, Rohan Banerjee, Soumoditya Banerjee · 2026 · BENTHAM SCIENCE PUBLISHERS eBooks
  7. Prescribing Pattern in Patients with Parkinsonism Attending Out-Patient Clinic in Tertiary Care Centre in North India
    Prachi Chauhan, Arpita Singh, Dinkar Kulshreshtha, Shaili Jaiswal, Rakesh Dixit · 2026 · International Journal of Science and Healthcare Research
  8. Expanding landscape of tau pathology in neurological disorders: A narrative review guiding diagnostic development and targeted therapeutics
    A. Yakubu, G. Atafo, C. Nwaze, T. Bakare, Temilade Oluwatoyosi Adeniyi, Kehinde P. Alare, Ac Oladele, O. Solagbade · 2026 · NeuroMarkers
  9. Identification and Characterization of New Therapeutic Targets in Acute Myeloid Leukemia
    Lina Benajiba · 2018 · theses.fr (ABES)
  10. Neurotoxicité précoce et mécanismes de neuroprotection dans des modèles poisson‐zèbre de tauopathies
    Clément Barbereau · 2020 · theses.fr (ABES)
  11. Role of T-cell immunity in the pathophysiology of Alzheimer’s disease and other Tauopathies
    Karen Matta · 2024 · theses.fr (ABES)
  12. Tau Aggregation Modulators
    Ibrar Ahmed Siddique, Megan Hong, Gal Bitan · 2026 · Topics in medicinal chemistry
  13. A Systematic Review on Disease‐Modifying Therapies in Parkinsonian Disorders
    Pepijn P.N.M. Eijsvogel, Lars M. G. Smits, Philip H. C. Kremer, Geert Jan Groeneveld · 2026 · Clinical Pharmacology & Therapeutics
  14. Targeting autophagy-related serine/threonine kinases to combat neurodegenerative disorders
    Wei Liu, Bo Liu · 2026 · Elsevier eBooks
  15. Splicing kinases in neuronal health and neurodegeneration
    Dalia S. El‐Gamil, Michael Emad, Sarah S. Darwish, Tsong‐Long Hwang, Ashraf H. Abadi, Matthias Engel, Mohammad Abdel‐Halim · 2026 · Elsevier eBooks
  16. Neuroinflammation and Tauopathies
    Marie-Noel Zeenny, I Salame, Lynn Maatouk, Elias Akoury · 2026 · Molecular Biology Reports
  17. Phase 2a Randomized Controlled Trial of TPN ‐101, A Nucleoside Reverse Transcriptase Inhibitor, in Progressive Supranuclear Palsy
    Andrew Satlin, Michael G. Cordingley, Debra K. Liebert, Walter Bee, Ethan G. Geier, John M. Sedivy, Jay Soto, Jianmin Duan, Samuel P. Dickson, Leslie Chu et al. · 2026 · Movement Disorders
  18. Longitudinal Cognitive Function in Progressive Supranuclear Palsy—A Review of the Evidence for Progression
    Timothy P Siejka, Kelly Bertram, Helmut Butzkueven, David Darby, Amy G. Brodtmann · 2026 · Movement Disorders Clinical Practice
  19. Frontotemporal lobar degeneration therapeutic development pipeline: 2026
    Alberto Benussi, Aurora Saccavini, Federica Palacino, Bradley F. Boeve, Adam L. Boxer, Edward D. Huey, Isabelle Le Ber, Raffaella Migliaccio, Chiadi U. Onyike, Olivier Piguet et al. · 2026 · Alzheimer s & Dementia Translational Research & Clinical Interventions
  20. BindingDB Entry 50015580: Glycogen Synthase Kinase 3β: A New Gold Rush in Anti-Alzheimer's Disease Multitarget Drug Discovery?
    BindingDB · 2023 · UC San Diego
  21. BindingDB Entry 50015003: Discovery of Novel Benzothiazepinones as Irreversible Covalent Glycogen Synthase Kinase 3β Inhibitors for the Treatment of Acute Promyelocytic Leukemia.
    BindingDB · 2023 · UC San Diego
  22. BindingDB Entry 50001652: Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
    BindingDB · 2020 · UC San Diego
  23. BindingDB Entry 50000052: Subtly Modulating Glycogen Synthase Kinase 3β: Allosteric Inhibitor Development and Their Potential for the Treatment of Chronic Diseases.
    BindingDB · 2019 · UC San Diego
  24. BindingDB Entry 50002050: Discovery of new GSK-3β inhibitors through structure-based virtual screening.
    BindingDB · 2020 · UC San Diego
  25. BindingDB Entry 50017353: Small-Molecule Kinase Inhibitors for the Treatment of Nononcologic Diseases.
    BindingDB · 2023 · UC San Diego
  26. Genetics of Atypical Parkinsonism
    María Stamelou, Kailash P. Bhatia · 2015 · Springer eBooks